ROME Therapeutics Appoints Scientist and Entrepreneur Scott Biller, Ph.D. to Board of Directors
ROME Therapeutics Appoints Scientist and Entrepreneur Scott Biller, Ph.D. to Board of Directors
Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease
Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
Decibel Therapeutics Announces Pricing of Initial Public Offering
Decibel Therapeutics Announces Pricing of Initial Public Offering
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer
Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer
Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease
Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease
Fractyl Announces Publication of Clinical Results from INSPIRE Study Showing Durable Insulin-Free Glycemic Control in Majority of Patients Treated
Fractyl Announces Publication of Clinical Results from INSPIRE Study Showing Durable Insulin-Free Glycemic Control in Majority of Patients Treated
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates
Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates
Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing
Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing
Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
ROME Therapeutics Appoints Scientist and Entrepreneur Scott Biller, Ph.D. to Board of Directors
Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer
Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease
Fractyl Announces Publication of Clinical Results from INSPIRE Study Showing Durable Insulin-Free Glycemic Control in Majority of Patients Treated
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing
Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer